Vivos Therapeutics shares are trading lower by 25% Thursday morning. The company announced a $4.3 million registered offering ...
On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, ...
The gross proceeds to the Company from the offering are expected to be approximately $4.3 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The ...
In recent trading, Vivos Therapeutics Inc (VVOS) stock price has shown some volatility, fluctuating 4.41% over the last five trades and 8.57% over the past 30 trades. This represents a notable shift ...
Vivos Therapeutics, Inc. (VVOS) announced on Wednesday that it has obtained 510(k) clearance from the FDA for its DNA oral medical ...
Vivos Therapeutics (VVOS) stock gains as company receives FDA clearance for its DNA appliance to treat obstructive sleep ...
Vivos Therapeutics is a pioneering medical device and technology company focused on addressing sleep-related breathing disorders (SRBDs), particularly obstructive sleep apnea (OSA). Their flagship ...
Vivos Therapeutics shares dropped Thursday after the company said it is offering 1.4 million common shares at $3.15 per share in a registered direct offering. Shares were down 27% to $3.03 in recent ...
LITTLETON, Colo., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the ...
Vivos Therapeutics shares are trading lower by 25% Thursday morning. The company announced a $4.3 million registered offering. Vivos Therapeutics Inc VVOS shares are trading lower by 26.1% to $3 ...
Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related ...